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Genetic screens in simple model organisms have identified
many of the key components of the conserved signal trans-
duction pathways that are oncogenic when misregulated.
Here, we identify H37N21.1 as a gene that regulates vulval
induction in let-60(n1046gf), a strain with a gain-of-function
mutation in the Caenorhabditis elegans Ras orthologue, and
show that somatic deletion of Nrbp1, the mouse orthologue
of this gene, results in an intestinal progenitor cell pheno-
type that leads to profound changes in the proliferation and
differentiation of all intestinal cell lineages. We show that
Nrbp1 interacts with key components of the ubiquitination
machinery and that loss of Nrbp1 in the intestine results in
the accumulation of Sall4, a key mediator of stem cell fate,
and of Tsc22d2. We also reveal that somatic loss of Nrbp1
results in tumourigenesis, with haematological and intest-
inal tumours predominating, and that nuclear receptor
binding protein 1 (NRBP1) is downregulated in a range of
human tumours, where low expression correlates with a
poor prognosis. Thus NRBP1 is a conserved regulator of cell
fate, that plays an important role in tumour suppression.
The EMBO Journal (2012) 31, 2486–2497. doi:10.1038/
emboj.2012.91; Published online 17 April 2012
Subject Categories: signal transduction; molecular biology of
disease
Keywords: intestine; progenitor cell; Ras; tumour suppressor
gene; WNT
Introduction
Perturbation of RAS, WNT or NOTCH signalling in the
C. elegans vulva results in defects in vulval development,
and many genetic screens have exploited this fact to identify
important components of these pathways. In humans, the
RAS, WNT and NOTCH pathways play an important role in
orchestrating embryonic development and may be dysregu-
lated in tumourigenesis. In the intestine, these pathways play
critical roles in lineage specification and are essential for the
normal formation of the bowel. Importantly, stem cells at the
base of the intestinal crypt express the leucine-rich repeat-
containing G-protein coupled receptor 5 (Lgr5) and are the
progenitors from which all other cell types of the intestine
(enterocytes, Paneth cells, goblet cells and enteroendocrine
cells) are generated. Daughter cells of the Lgr5þ stem cells,
called transit-amplifying cells, divide every 12–16 h generat-
ing some 300 cells per crypt per day and drive the replenish-
ment of the intestinal epithelium, which is completely
renewed every 5 days (Barker et al, 2009). Therefore,
disruption of the fine balance between differentiation and
proliferation by perturbing key signalling pathways has a
profound effect on the ability of the intestine to regenerate
and function.
Using RNAi in C. elegans, we performed a kinome-wide
screen and identified the worm orthologue (H37N21.1) of the
nuclear receptor binding protein 1 (NRBP1) as a novel
enhancer of the RAS-induced multivulval phenotype (Muv)
in a let-60(1046gf) gain-of-function mutant background.
NRBP1 is located on human chromosome 2p23 and encodes
a 535 amino-acid protein. It is ubiquitously expressed and
highly conserved (Hooper et al, 2000). NRBP1 is a
pseudokinase because it lacks critical catalytic residues in
the kinase core, and carries a highly degraded ATP-binding
site (Boudeau et al, 2006). In addition to its kinase-like
domain, NRBP1 has a putative binding domain for Src
homology-2-containing proteins, nuclear export signals, a
nuclear localisation signal, a BC-box motif and a binding
site for the myeloid leukaemia factor 1 (Gluderer et al, 2010).
Here, we show that somatic deletion of Nrbp1 in the mouse
causes a progenitor cell phenotype that disrupts the normal
programme of cellular differentiation and proliferation along
the intestinal crypt–villus axis. We also show that knock-
down of NRBP1 cooperates with RasV12 to elicit transforma-
tion. Importantly, we show that loss of Nrbp1 increases the
level of Sall4 and Tsc22d2 in the intestine where they
associate with Nrbp1 and components of the ubiquitination
machinery. In addition, we reveal that Nrbp1 is a tumour
suppressor in mice and that NRBP1 is downregulated in a
range of human cancers where low expression is associated
with a poor clinical outcome. Thus, we identify critical roles
for an uncharacterised gene through a combination of genetic
screening in the worm and detailed functional analysis in the
mouse and in human cells.
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Results
Identification of H37N21.1 in a kinome-wide RNAi
screen in let-60(n1046gf) worms
C. elegans that are homozygous for a gain-of-function allele
of the worm Ras orthologue let-60(n1046gf) have a partially
penetrant Muv phenotype with B60% of worms being Muv
at 16 1C. The let-60(n1046gf) allele encodes an activating
mutation in LET-60 that is functionally analogous to the
codon 13 Gly4Glu mutation in RAS found in human tumours
(Beitel et al, 1990). Multiple genetic screens have been
carried out to identify genes whose loss suppresses the
Muv phenotype in let-60(n1046gf) animals, and these have
resulted in the isolation of many oncogenes acting in the RAS
signalling pathway. Here, we use RNAi to identify genes
whose loss enhances the Muv phenotype of let-60(n1046gf)
reasoning that orthologues of these genes might function as
tumour suppressors by perturbing the WNT, NOTCH or RAS
pathways, which are critical to the formation of the worm
vulva. This is the first such screen for enhancers of the Muv
phenotype in let-60(n1046gf).
We adapted standard RNAi screening protocols (Fraser
et al, 2000) to establish screening conditions in which we
could robustly identify three previously characterised
enhancers (egr-1, egl-27 and nhl-2) (Solari and Ahringer,
2000; Hammell et al, 2009) of the let-60(n1046gf) Muv
phenotype. RNAi clones targeting all 656 genes in the worm
genome with kinase homology were then screened
(Figure 1A). For each gene, B500 worms were examined
and scored for the number of vulva. In this way, we identified
10 genes as suppressors of the Muv phenotype in
let-60(n1046gf), and 6 genes as enhancers (Figure 1A). We
re-assayed these genes through three confirmatory rounds of
screening and identified four consistent enhancers of the
let-60(n1046gf) Muv phenotype (Figure 1B): dgk-2/F46H6.2,
H37N21.1, mig-15/ZC504.4 and hpk-1/F20B6.8.
dgk-2 encodes a diacylglycerol (DAG) kinase, and coopera-
tion between activating mutations in RAS and DAG-activated
signalling pathways in mammalian transformation assays is
well established (Castagna et al, 1982; Nakamura et al, 1989).
We confirmed that dgk-2 loss enhances the let-60(n1046gf)
Muv phenotype using a mutant (null) allele of dgk-2 (dgk-
2(gk124)); worms homozygous for dgk-2(gk124) showed no
obvious phenotype, whereas 100% of let-60(n1046gf); dgk-
2(gk124) double-mutant worms showed the Muv pheno-
type due to hyperinduction of vuval progenitor cells (data
not shown). In contrast, the mechanism of action for the
other three genes was less clear; mig-15 encodes a Nick-
interacting kinase homologue that is known to play a role in
cell migration and has been implicated in integrin and WNT
signalling (Poinat et al, 2002); hpk-1 encodes a homeo-
domain-interacting kinase homologue, and H37N21.1
encodes an orthologue of the adapter protein NRBP1.
gap-1 encodes a member of the Ras GTPase-activating
protein family and negatively regulates the let-60 pathway
with respect to vulval development. Worms homozygous for
a gap-1 loss-of-function allele (gap-1(ga133)) show normal
vulval induction (vulval index¼ 3.0) (Hajnal et al, 1997);
however, loss of negative regulators of Ras signalling such as
lip-1 (Berset et al, 2001) can yield a Muv phenotype in these
mutants (vulval index43.0). RNAi targeting of H37N21.1 in
gap-1(ga133) mutants resulted in 17% of worms displaying
the Muv phenotype (vulval index of 3.7); however, no vulval
defects were observed when H37N21.1 was targeted by RNAi
in wild-type worms (vulval index of 3.0). This phenotype is
indicative of a hyperactivated LET-60 signalling cascade. To
further implicate LET-60 signalling, we used a more sensitive
assay (egl-17Hcfp) that reports on the levels of LET-60
signalling, without the gap-1 mutation in the background,
and directly in the vulval cells. Normally, only the
descendants of P6.p will express CFP because it receives
the highest amount of EGF (LIN-3), but not P5.p or P7.p
descendants. We found that worms depleted of H37N21.1
ectopically express CFP and are therefore displaying
excessive LET-60 signalling (Figure 1C). Thus we focused
our efforts on H37N21.1. H37N21.1 is an orthologue of
NRBP1 and shows 57.3% amino-acid sequence identity.
NRBP1 and Nrbp1 from mouse show 99.6% amino-acid
sequence identity (Supplementary Figure 1).
Knockdown of NRBP1 cooperates with activated Ras to
induce transformation
To determine if NRBP1 interacts with the RAS pathway in
mammals, we performed focus formation assays in murine
NIH3T3 fibroblasts. Cells stably transfected with Nrbp1
shRNA did not form foci. In contrast, cells transfected with
pBabe-RasV12 showed a modest number of transformed foci;
however, transfection of pBabe-RasV12 into cell lines expres-
sing shRNAs against Nrbp1 resulted in a significant number
of foci (in 3/4 Nrbp1 shRNAs assayed; Figure 1D).
Knockdown of Nrbp1 protein was confirmed by western
blotting (Figure 1E). In agreement with these findings,
shRNA-mediated stable knockdown of NRBP1 in the BJ-ET-
st p53kd, p16kd human fibroblast cell line, which readily
transforms following subtle perturbation of the RAS pathway
or the pathways that regulate the RAS signalling cascade
(Voorhoeve and Agami, 2003), resulted in a significant
increase in the number of transformed colonies in soft agar
(in 5/6 NRBP1 shRNAs assayed; Figure 1F). However, stable
repression of NRBP1 saw no increase in the activation of RAS
as assayed by western blotting following pull-down using
GST-Raf1-BSD (Figure 1G). Thus, just as knockdown of
H37N21.1 in C. elegans cooperates with gain-of-function
mutations of let-60, knockdown of NRBP1 cooperates with,
but does not directly activate, RAS in the transformation
of mammalian cells in culture. To follow this further, we
examined the effect of Nrbp1 loss in vivo.
Generation and analysis of Nrbp1 conditional and
knockout mice
To examine the effect of loss of Nrbp1 in vivo, we created a
conditional knockout mouse model. The targeting vector con-
sisted of 9.6kb of homology to the Nrbp1 locus, with a loxP site
inserted in intron 4, and a flrted PGK–neomycin selection
cassette and second loxP site inserted in intron 11 (Figure 2A).
Correctly targeted E14J ES cells were identified by Southern blot
analysis (Figure 2B). Knockout (Nrbp1þ / ) and conditional
(Nrbp1þ /flox) Nrbp1 alleles were established in mice by breeding
male chimeras with Cre and Flp deleters, respectively
(Figure 2C). Excision of exons 5–11 disrupts the kinase-like
domain of Nrbp1 and we hypothesised that this would result
in nonsense-mediated decay of the remaining transcript.
Mice heterozygous for the knockout Nrbp1 allele
(Nrbp1þ / ) were grossly normal at birth and fertile (data
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not shown); however, homozygosity resulted in embryonic
lethality at day E7.5 (Supplementary Figure 2). Therefore,
loss of Nrbp1 is not essential for cell viability (since null
embryos are able to implant) but defects in or after gastrula-
tion appear to result in embryonic lethality.
Perturbation of proliferation and differentiation of the
intestinal epithelium following conditional loss of
Nrbp1
To establish the phenotypic effects of somatic loss of Nrbp1,
conditional Nrbp1 mice (Nrbp1flox/flox and Nrbp1flox/ ) were
intercrossed with mice carrying the RosaCreERT2 allele
(RosaCreERT2/CreERT2), which express Cre-ERT2 protein ubiqui-
tously, and at all developmental stages (Hameyer et al,
2007). At 7–8 weeks of age, Nrbp1flox/flox RosaCreERT2/þ
or Nrbp1flox/ RosaCreERT2/þ mice (which showed no
phenotypic differences from each other and hereafter are
collectively referred to as cKO mice) and Nrbp1flox/flox
Rosaþ /þ , Nrbp1þ / RosaCreERT2/þ or Nrbp1flox/þ
RosaCreERT2/þ mice (hereafter collectively referred to as
control mice) were dosed with tamoxifen (intraperitoneal
injection of 4 mg tamoxifen for three consecutive days).
cKO mice became moribund as early as 3 days after dosing
(n¼ 11/28) and 75% died or became moribund by day 9
(n¼ 21/28, Figure 2D). In contrast, no control mice died
within 174 days post treatment (Figure 2D; Po0.0001).
cKO mice showed macroscopically distended stomachs
where food had failed to pass into the intestines and oede-
matous intestinal tracts with an abnormal mucosal appear-
ance. Histopathological analysis of the brain, kidneys, skin,
thymus, heart, pancreas, lungs, uterus/testis and spleen of
control and cKO mice revealed no abnormalities. However,
cKO mice showed zone 3 hydropic changes in their livers,
indicative of malnutrition (data not shown), and the intes-
tines showed a complete loss of architecture, including
reduced numbers of differentiated cells, cells showing dys-
plastic nuclear atypia, widespread crypt elongation by primi-
tive looking cells and reduced villous length (Figure 2E). An
increased level of crypt fission was also observed (Figure 2F).
To examine the expression pattern of Nrbp1 in the intestine,
we performed in situ hybridisation (ISH) analysis using a
probe specific to the conditionally deleted region of Nrbp1. In
control intestines, expression of Nrbp1 was found to be
highest in the Paneth, enteroendocrine and precursor goblet
cell lineages; however, Nrbp1 expression was also found in
the crypt and to overlap with the Lgr5 and Olfm4-positive
stem cells (Supplementary Figure 3). To confirm the specifi-
city of the Nrbp1 in situ probe, we analysed tamoxifen-treated
cKO tissues and as expected little or no Nrbp1 expression was
observed (Figure 2G). Similarly, western blotting showed a
downregulation in Nrbp1 protein levels in the intestine of
tamoxifen-treated cKO mice (Figure 2G).
Figure 1 C. elegans let-60 (n1046gf) RNAi kinase screen and mammalian in vitro transformation analysis. (A) Muv phenotype of let-60
(n1046gf) worms after RNAi-mediated knockdown of 656 worm kinase genes. The percentage of animals with a multivulva phenotype is
shown. (B) We took the top 2% of genes and performed a second round of screening to identify four robust enhancers of the Muv phenotype.
(C) RNAi against H37N21.1 causes excessive LET-60 signalling in vulval cells. egl-17Hcfp transgenic worms showing ectopic expression of CFP
in P5.p descendants after one cell division (P5.px), which indicates excessive LET-60 signalling. Also shown is the normal CFP expression in
the P6.p descendants (P6.px). We observed ectopic expression at a rate of 18% (n¼ 23). Top image is light field and bottom image is CFP
expression. (D) Histogram of colony numbers from transformants derived from NIH3T3 cells cotransfected with an Nrbp1 shRNA vector (1–4)
and pBabe-RasV12 vector. pBabe-RasV12 vector alone (R) and empty pBabe vector (N) were used as controls. (E) Western blot analysis of Nrbp1
knockdown in NIH3T3 cells. (F) Histogram of transformants after BJ-ET-st p53kd, p16kd cells were transfected with NRBP1 human shRNA
vectors (1–6) or pRS empty vector control (N). (G) BJ-ET-st p53kd, p16kd transformed colonies transfected with human NRBP1 shRNA vector 3
were picked, cultured and whole-cell lysates collected for use in pull-down assays using GST- Raf1-BSD. Lysates were separated and visualised
using a pan-RAS antibody (L—whole cell lysate, GTP—positive control, GDP—negative control, N—untransfected control cell pull-down,
3—shRNA trasformant pull-down). Data are represented as mean±s.d.; *Po0.05, **Po0.01. All shRNA hairpin sequences are available in the
Supplementary methods. ***Po0.001.
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Figure 2 Generation and characterisation of Nrbp1 knockout mice. (A) Schematic representation of the Nrbp1 locus, along with targeted,
conditional and knockout Nrbp1 alleles. The PGK–neomycin selection cassette (neo) is flanked by Frt sites (striped triangles). Open triangles
indicate LoxP sites for conditional deletion of exons 5–11. (B) Confirmation of correct targeting was performed by Southern blot analysis of
BamHI-digested DNA; The wildtype band for both 50- and 30-probes was 11.6 kb and the targeted band was 3.8 and 4.3 kb, respectively.
(C) Subsequent genotyping was performed by PCR, using either primers ‘b/c’ to detect the wild-type and conditional allele, or primers ‘a/c’ to
detect the knock out allele. (D) Survival curve of Nrbp1flox, RosaCreERT2/þ (cKO) mice and controls after intraperitoneal dosing with 3 mg
tamoxifen per day for 3 days. (E) H&E staining of the SI (small intestine) and LI (large intestine) from C (control; Nrbp1þ / RosaCreERT2/þ or
Nrbp1flox/þRosaCreERT2/þ ) and cKO (Nrbp1flox/flox RosaCreERT2/þ or Nrbp1flox/ RosaCreERT2/þ ) mice at 5–7 days post tamoxifen treatment
showing crypt elongation by primitive looking cells ( 200 magnification). Inset: cKO intestines show evidence of crypt fission. (F) cKO mouse
intestines had more crypts per field of view than C intestines at 4–5 days post dosing. (G) (i) ISH analysis using probe specific to Nrbp1 in the SI
(small intestine) and LI (large intestine) of C mice (control;  400 magnification) and the SI of cKO mice ( 200 magnification) at 5 days post
tamoxifen treatment, showing reduction of Nrbp1 expression levels in cKO tissue. (G) (ii) Western blot analysis of intestinal tissue harvested
from C and cKO mice at 5 days post treatment with 1 mg tamoxifen for 4 days shows a reduction of Nrbp1 protein levels. b-Actin levels used as
a control. (H) Histological and immunohistological analysis showing cKO mouse intestines had fewer goblet cells (as determined by Alcian
blue staining) and an altered distribution of Paneth cells (as determined by lysozyme staining) compared to C mice at 4–5 days post dosing.
*Po0.05. (I) cKO mice had more proliferating cells (as determined by Ki67 immunopositivity) than C intestines at 4–5 days post dosing. Data
are represented as mean±s.d.; *Po0.05. (J) Histological and immunohistochemical analysis of the small intestines of 7–8-week-old
Nrbp1 /cLgr5-EGFP-IRES-CreERT2þ and Nrbp1 /þLgr5-EGFP-IRES-CreERT2þ control mice at 4–5 post dosing with 1 mg tamoxifen for 3
days. Data are represented as mean þ / s.d. (n¼ 6 per genotype). Stem cell-specific deletion of Nrbp1 resulted in abnormal paneth cell
localisation and granulisation, and abnormal goblet cell production ( 200 magnification; haematoxylin and eosin, H&E; anti-lysozyme
antibody, LY; Alcian blue, AB). **Po0.01, ***Po0.001.
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Histological analysis of each of the cell types that constitute
the intestinal epithelium, revealed most notably a marked
decrease in the number of Alcian Blue positive goblet cells,
an altered distribution of Paneth cells (Figure 2H) and reduced
enteroendocrine cells (Supplementary Figure 3). In addition,
expression of the proliferation marker Ki67 and the number of
mitotic figures were significantly increased, while expression
of the apoptotic marker cleaved caspase 3 was not significantly
changed (Figure 2I, Supplementary Figure 3). To further
investigate the phenotypic effect of Nrbp1 deficiency specifi-
cally within the intestinal stem cell compartment, we utilised
the Lgr5-EGFP-IRES-CreERT2 knock-in mouse, which expresses
CreERT2 specifically within the Lgr5-positive stem cell com-
partment with recombination occurring in a sporadic
and low-penetrant fashion (o10% intestinal stem cells)
upon tamoxifen treatment (Barker et al, 2007; Barker et al,
2009). Immunohistochemical analysis of small intestines from
Nrbp1 /cLgr5-EGFP-IRES-CreERT2þ mice at 5 days post
tamoxifen treatment (intraperitoneal dosing of 1 mg/ml
tamoxifen for 3 days) showed a similar phenotype to cKO
mice, albeit to a lesser extent due to the very low level of
recombination, with Paneth cells displaying abnormal
localisation and granularisation, and abnormal goblet cell
production (Figure 2J).
Together, these data indicate that loss of Nrbp1 protein in
the adult intestines of mice causes aberrant proliferation of
progenitor-like cells in the crypts and increased crypt fission,
which profoundly affects the normal programmes of cellular
differentiation and localisation along the crypt–villus axis.
These features are similar to several mouse models engi-
neered to perturb the WNT pathway (Batlle et al, 2002;
Sansom et al, 2004; Madison et al, 2005; Finch et al, 2009).
Expression profiling of Nrbp1-deficient intestinal cells
To evaluate the role of loss of Nrbp1 in intestinal homoeo-
stasis, we performed microarray expression profiling on small
intestinal epithelial cells from tamoxifen-dosed control and
cKO mice. For these experiments the Cre driver used was
RosaCreERT2/þ . The expression of 3331 genes was significantly
altered (Po0.01 to 2 decimal places between these groups
(Supplementary Table 1). Interestingly, a number of WNT-
responsive genes showed significantly increased expression
in cKO mice compared with controls, including Ccnd1, Cd44,
Mmp7, Sox9 and Tnfrs12a.
To validate the expression arrays, we examined the expres-
sion of a number of WNT-responsive genes by quantitative
RT–PCR (qRT–PCR). Expression of Cd44, c-Myc and Ccnd1
were upregulated more than three-fold in the intestinal
epithelium of cKO mice compared with controls
(Figure 3A). Further examination of WNT target genes by
immunohistochemistry and ISH analysis of the small intes-
tines revealed increased staining for c-Myc, Sox9, Mmp7 and
Lgr5 in cKO mice compared with controls (Figure 3B). In
addition, cKO mice showed a widespread increase in pErk
nuclear positivity and b-catenin staining in the mucosa that
matched the upward spread of crypt progenitor-like cells
(Figure 3C). In addition, although the clearest signature
was for the WNT pathway, we note that a number of other
signalling pathways were also significantly altered—for
example, expression analysis of the Notch genes revealed
that Notch3 and Notch4 were both significantly overexpressed
and this in turn lead to an increase in Hes1 expression
(Supplementary Figure 4).
We next compared our differentially expressed gene set to
gene expression signatures of genetic and chemical perturba-
tions using the Molecular signatures database MSigDB
Version 2.5 (http://www.broadinstitute.org/gsea/msigdb/
index.jsp) (Subramanian et al, 2005). There was a striking
overlap (P¼ 5.89 e 23 and P¼ 5.5 e 47) with genes down-
regulated at 4 or 5 days following conditional deletion of
adenomatous polyposis coli (Apc) in the mouse intestine
(Sansom et al, 2004) (Supplementary Figure 5). Similarly,
there was a significant overlap between genes that were
upregulated upon loss of either Apc or Nrbp1 (P¼ 0.007
(5 days) P¼ 6.2E 06 (4 days); Supplementary Figure 5),
suggesting that similar changes to the programmes of gene
expression occur following loss of either gene. These expres-
sion changes may also reflect changes in the constitution of
the cells that make up the intestinal epithelium.
To further investigate the role of Nrbp1 within the intestine,
we grew Nrbp1 cKO and control crypts ex vivo. Using
adenoviral cre infection of organoid cultures to delete
Nrbp1, we observed decreased organoid budding and orga-
noid dis-organisation (Supplementary Figure 6). After long-
term culture of these organoids they eventually regained the
ability to bud, presumably due to the outgrowth of non-
recombined cells (Koo et al, 2011). On removal of R-spondin
from early cultures all crypts of all genotypes died, indicating
that Nrbp1 null crypts are still dependant on Wnt signalling.
Nrbp1 interacts with Elongin BC E3 ubiquitin ligase
complex
To further explore possible roles for Nrbp1 within mammalian
cells, we performed tandem affinity purification followed by
mass spectrometric analysis using a FTAP-tagged human
NRBP1 cDNA expression plasmid in mouse ES cells (E14J;
129P2/Ola). Five proteins were shown to bind strongly to
NRBP1, including Tceb1 (Elongin B), Tceb2 (Elongin C),
Tsc22d2, Tsc22d4 and Sall4 (Supplementary Table 2). To vali-
date these results, we performed single affinity purifications
from human HEK293 cells expressing the same FTAP-tagged
human NRBP1 cDNA. We were able to recover TCEB1, TCEB2,
TSC22D2 and TSC22D4, among others. SALL4 was not recov-
ered, most likely due to the stem cell-specific expression of
SALL4; we therefore confirmed that Sall4 binds to Nrbp1 in
mouse ES cells by coimmunoprecipitation (Figure 4A). We also
confirmed binding of Nrbp1 to Elongin B and Elongin C by
coimmunoprecipitation (Figure 4B). Since ELONGIN B and the
TSC22s have been shown to bind to NRBP1, and NRBP1 carries
both a functional Elongin BC-binding motif (BC-Box) and a
CUL5-binding site (Supplementary Figure 1) (Rual et al, 2005;
Mahrour et al, 2008; Gluderer et al, 2010), we hypothesised that
it may function as a substrate recognition subunit of a Cul5 E3
ligase complex. Indeed, expression of NRBP1, ELONGIN B,
ELONGIN C and CUL5 in HEK293 cells allowed coimmuno-
precipitation of CUL5 with NRBP1, only when ELONGIN B and
ELONGIN C were present in the lysate (Figure 4B). This is in
contrast to a previous report suggesting that NRBP1 is not part
of a complex with CUL5 (Mahrour et al, 2008). To further
investigate if NRBP1 could be functioning within an Elongin BC
E3 ubiquitin ligase complex, we performed western blot and
immunohistochemical analysis on intestinal tissue from
tamoxifen-treated cKO mice and found a significant increase
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in both Tsc22d2 and Sall4B protein levels compared to controls
(Figures 4C and D and Supplementary Figure 7) suggesting that
Nrbp1 may have a role in the turnover or accumulation of these
proteins. It is, however, important to note that as yet we have
been unable to functionally link Nrbp1 to the ubiquitination of
these proteins. Intriguingly, overexpression of SALL4 has been
shown to play a role in regulating the WNT pathway in the
haematopoietic system through a direct physical interaction
with b-catenin (Ma et al, 2006). Here, we show that knock-
down of NRBP1 or overexpression of SALL4 in HCT-116 human
colon cancer cells results in an upregulation of WNT reporter
activity (Figure 4E) suggesting a direct link between NRBP1
and the WNT pathway through SALL4, an avenue we are
currently investigating further.
Nrbp1 is a tumour suppressor in vivo
Given Nrbp1 proficiency is vital for intestinal homoeostasis
and loss of Nrbp1 cooperates with oncogenic Ras and can
modulate Wnt signalling, we hypothesised that Nrbp1 may be
a tumour suppressor in vivo. In our initial survival analysis
(Figure 2D), 18% (n¼ 5) of cKO mice survived the acute
intestinal phenotype associated with loss of Nrbp1, and
histological analysis of their intestines revealed no abnorm-
alities. This suggested incomplete recombination of the
Nrbp1 allele and intestinal regeneration by the surviving
cells (Muncan et al, 2006). To generate a cohort of mice for
tumour watch, we treated 7–8-week-old control and cKO
mice with a lower dose of tamoxifen (intraperitoneal dose
of 1 mg tamoxifen for four consecutive days) and placed them
on tumour watch. cKO mice showed significantly reduced
survival compared to controls, which was associated with
an increased incidence of tumourigenesis, including
lymphomas/leukaemias and solid tumours (P¼ 0.006;
Figure 5A–C). Interestingly, 38% (6/16) of the cKO mice
displayed gastrointestinal tract tumours, specifically four
were adenomas with high-grade dysplasia and two were
invasive adenocarcinoma (5/6 tumours were located in the
caecum; Figure 5B). In situ analysis of these tumours con-
firmed loss or reduction in Nrbp1 RNA levels (Figure 5Di),
and immunohistochemical analysis showed widespread nu-
clear c-Myc and pErk staining (Figure 5Dii–iv), analogous to
the staining patterns identified in the ‘early Nrbp1-null phe-
notype’. Taken together, these data are all consistent with a
role for Nrbp1 as a tumour suppressor gene in vivo.
Reduction in Nrbp1 expression is seen in a wide variety
of human tumours and correlates with poor prognosis
To further explore the association of NRBP1 loss in cancer, we
performed expression analysis on a wide variety of human
tumour types (including leukaemia, lymphoma, colorectal,
breast, brain, oesophageal, renal cell, prostatic and lung
cancers) and found significantly reduced NRBP1 expression
levels in many of these tumour types when compared with
relevant control tissues (Po0.01; Figure 6A). As lung adeno-
carcinoma showed the most significant difference in NRBP1
expression levels between normal and tumour tissues, and
survival analysis data was available, we examined the rela-
tionship between NRBP1 expression and survival and found
that low NRBP1 expression strongly correlated with a poor
prognosis (P¼ 0.008; Figure 6B).
Discussion
Cancer is a multistep process that requires extensive synergy
between oncogene activation and tumour suppressor gene loss.
Many oncogenes are key components of highly conserved
signalling pathways, and genetic screens in model organisms
including Drosophila and C. elegans have identified oncogene
orthologues in the EGF, WNT, NOTCH and TGFb pathways,
among others. However, such screens have yielded few ortho-
logues of tumour suppressor genes. In this paper, we employed
the power of RNAi screening in C. elegans to identify candidate
tumour suppressor genes by screening for genes that enhanced
developmental defects due to gain-of-function mutations in
Ras. Importantly, we found that loss of H37N21.1, the worm
orthologue of NRBP1, enhanced the effect of gain-of-function
mutations in Ras suggesting that it may act as a tumour
suppressor gene in mammals.
NRBP1 is a highly conserved adaptor protein that we show
is required for early mouse embryonic development.
In mammalian in vitro systems, we have shown that together
with oncogenic RAS, NRBP1 knockdown leads to an increase
in transformation; however, NRBP1 loss does not appear to
Figure 3 Expression analysis of conditional Nrbp1 mice. (A) qRT–PCR analysis of the WNT target genes, Cd44, c-Myc and Ccnd1 in the
intestine of cKO and C mice at 4–5 days post tamoxifen administration. (B) Immunohistochemical (i, ii) and in situ analysis (iii, iv) of small
intestines from C and cKO mice at 7–9 days post tamoxifen treatment indicating loss of Nrbp1 causes an increase in (i) c-Myc ( 400
magnification), (ii) Sox9 ( 400 magnification), (iii) Mmp7 ( 400 magnification) and (iv) Lgr5 ( 200 magnification). (C)
Immunohistochemical analysis of small intestines from C and cKO mice at 7–9 days post tamoxifen treatment show increased expression
of (i) pErk ( 200 magnification), but no obvious increase in (ii) nuclear Ctnnb1 signal ( 400 magnification). *Po0.05, **Po0.01.
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affect RAS signalling directly suggesting that other pathways
must modulate RAS activity following NRBP1 loss. To inves-
tigate the function of Nrbp1 in vivo, we constructed a condi-
tional knockout mouse model. Two somatic phenotypes were
discerned depending on the pattern of Nrbp1 disruption.
First, there was an ‘early intestinal phenotype’ at 4–9 days
post tamoxifen dosing. This phenotype consisted of expan-
sion of crypt progenitor-like cells with aberrant proliferation
in elongated crypts and increased crypt fission, together with
abnormal differentiation and localisation of cells along the
crypt–villus axis. Ultimately this phenotype led to abnormal
intestinal function, malnutrition and the death of over 80%
mice by 5–10 days (Figure 2). The intestinal epithelia of these
mice showed several similarities to mouse models engineered to
perturb the WNT pathway (Batlle et al, 2002; Sansom et al,
2004; Madison et al, 2005; Finch et al, 2009). Interestingly,
the phenotype also shows a striking similarity to a model
in which the POU-family transcription factor Oct4 was
overexpressed in the intestine (Hochedlinger et al, 2005). We
tentatively speculate that Nrbp1 regulates Sall4 levels through
its role in an Elongin BC E3 ubiquitin ligase complex and thus
suggest that the intestinal phenotype of the Nrbp1 cKO mice
may possibly be due to increased levels of Sall4 influencing cell
fate by perturbing the WNT pathway, which tips the balance of
Figure 4 NRBP1 interacts with components of the Elongin BC E3 ubiquitin ligase complex. (A) Immunoprecipitation with anti-Flag antibody
of mouse ES cells carrying either Flag-tagged NRBP1 cDNA expression plasmid (N) or Flag-tagged Phactr2 cDNA expression plasmid (P) as a
control, followed by western blotting with one of two different anti-Sall4 antibodies (Ab1 and Ab2), showed coprecipitation of both Sall4
isoforms with Nrbp1 and not the control. In mouse ES cells, Sall4 has been shown to run at 85 and 140 kDa. (B) Immunoprecipitation of CUL5
and other members of the ubiquitination machinery with NRBP1 from HEK293 cells. (C) Western blot analysis with anti-Tsc22d2 antibody,
anti-Sall4 and anti-b-Actin control antibody of intestinal tissue harvested at day 5 from cKO (Nrbp1flox RosaCreERT2/þ ) or C (control; Nrbp1flox
Rosaþ /þ ) mice treated with 1 mg tamoxifen for 4 days. In somatic cells, Sall4 has been shown to run at 66 and 113 kDa.
(D) Immunohistochemical analysis of Sall4 in the intestinal tissue from C (control; Nrbp1floxRosaþ /þ ) and cKO (Nrbp1floxRosaCreERT2/þ )
mice at 4–5 days post tamoxifen treatment showing elevated levels of Sall4. (E) Transcriptional activation of TCF/LEF measured using the dual
luciferase assay (TOP/FOP) in HCT-116 colon cancer cells transfected with a Sall4 cDNA plasmid (left panel) or an NRBP1 shRNA construct
(middle panel). N refers to an empty vector control. Transcriptional activation of TCF/LEF was also measured by siRNA-mediated knockdown
of NRBP1 in SW180 WNT reporter cells (right panel). Knockdown of CTNNB1 was used as a control. *Po0.05, **Po0.01, ***Po0.001.
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progenitor cells from differentiation to proliferation. As yet,
however, we have been unable to conclusively prove this
functional link. Furthermore, although we were able to pull-
down complexes containing components of the ubiquitination
machinery and Nrbp1, we have been unable to conclusively
prove a role for Nrbp1 in protein turnover. Indeed, the data we
have collected on Nrbp1 suggest that it may have pleiotropic
effects on several pathways.
Most of the mice which survived this ‘early intestinal
phenotype’ went on to develop a wide range of tumours,
including intestinal adenomas in 38% of mice, a third of
which had advanced to invasive intestinal adenocarcinoma,
as well as lung adenocarcinomas, lymphomas, leukaemias
and angiosarcomas, with significantly reduced survival.
Thus, Nrbp1 acts as a tumour suppressor gene in vivo with
Nrbp1 loss resulting in a tendency to intestinal adenoma/
adenocarcinoma and lymphoma/leukaemia formation
(Figure 5). Analysis of human cancer expression datasets
showed that NRBP1 is downregulated in a range of tumour
types, and that in lung adenocarcinomas low NRBP1 expres-
sion is associated with a poorer prognosis (Figure 6). It is
intriguing to note that although we were able to recapitulate
the acute intestinal phenotype associated with loss of Nrbp1
by expressing CreERT2 specifically in Lgr5þ stem cells
(Figure 2J), and that loss of Nrbp1 activates the WNT path-
way (Figure 3), we have not observed intestinal polyposis or
tumourigenesis in Nrbp1 /cLgr5-EGFP-IRES-CreERT2þ mice
up to 100 days (data not shown). This may be because of
the modest activation of the WNT pathway we observed
and because fewer cells underwent recombination using the
Lgr5-EGFP-IRES-CreERT2 allele. In both models of Cre recom-
bination and in ex vivo crypt culture, it appears that selection
against Nrbp1 loss occurs suggesting that by itself Nrbp1
is unlikely to be an initiating event in colorectal cancer,
Figure 5 Nrbp1 is a tumour suppressor in vivo. (A) Survival analysis of cKO (NrbpfloxRosaCreERT2/þ ) and control mice (Nrbpflox/þRosaCreERT2/þ
and Nrbpflox/floxRosaþ /þ ) after treatment with 1 mg tamoxifen per day for 4 days. Animals became moribund and were culled as a result of
either an ‘early Nrbp1 loss phenotype’ (animals o10 days post treatment) or when they developed macro/microscopically visible tumour(s)
(animals 410 days post treatment). (B) Table provides a summary of the tumour types found in the mice (some animals had more than one
type of tumour). (C) H&E staining of tissues from cKO mice showing (i) widespread lymphoma in the liver ( 100 magnification), (ii) invasive
colorectal adenocarcinoma ( 250 magnification) and (iii) high-grade angiosarcoma in the spleen ( 250 magnification). (D) ISH analysis of
Nrbp1 in a colorectal lesion from an Nrbp1floxRosaCreERT2/þ mouse shows (i) a tumour area left of the black line, and normal colonic tissue right
of the black line ( 25 magnification), with the lower box enlarged in (ii) and the upper box enlarged in (iii), showing reduced Nrbp1
expression levels in tumour tissue ( 200 magnification). Immunohistochemical analysis of an invasive colorectal adenocarcinoma from an
Nrbp1floxRosaCreERT2/þ mouse showing significant strongly positive staining with (iv) c-Myc ( 400 magnification) and (vi) pErk ( 200
magnification) antibodies, but (v) no increased nuclear Ctnnb1 signal ( 400 magnification).
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instead cooperating mutations are likely to be required for
tumourigenesis.
We have shown that NRBP1 interacts with ELONGIN B and
C and CUL5, which are components of an E3 ubiquitin ligase
complex. The Elongin BC complex is a heterodimer com-
posed of ELONGIN C and ELONGIN B, that was initially
identified as a positive regulator of RNA polymerase II
elongation factor ELONGIN A (Reines et al, 1999). A more
recognised role of Elongin BC is within the tumour
suppressor complex together with the von Hippel-Lindau
(VHL) protein, which targets the transcription factor
hypoxia inducible factor-1a for ubiquitination (Duan et al,
1995; Kibel et al, 1995). Interaction of the Elongin BC
complex with proteins such as VHL and suppressors of
cytokine signalling (SOCS) depends on binding to a B10
amino-acid degenerate sequence motif, referred to as the
BC-box, which has the consensus sequence of [(A/P/S/T)-
L-X3-(C/S/A)-X3-(A/I/L/V)], a motif also present in NRBP1
(Supplementary Figure 1). The BC-box-containing protein
mediates substrate binding and specificity, while Elongin
BC functions as an adapter that links it to a Cullin/Rbx
module that functions to recruit and activate an E2 ubiqui-
tin conjugating enzyme for ubiquitylation of substrates.
In addition to VHL and SOCS, a number of novel BC-box
proteins have been shown to assemble with Cullin/Rbx and
therefore it has been predicted that a larger family of
ELONGIN BC-based E3 ubiquitin ligases exists (Kamura
et al, 2001). We therefore suggest that NRBP1 is involved in
substrate recognition within a RING-type E3–ligase complex
to enhance the ubiquitin-mediated degradation of proteins.
As yet, however, confirming this hypothesis has proved
elusive. Potential substrates of NRBP1 could include
TSC22d2 and SALL4, which we show bind strongly to
NRBP1 and both show increased protein levels in vivo
when Nrbp1 is deleted in the mouse (Figure 4). Sall4 is a
transcription factor that plays an essential role in maintaining
embryonic stem cell pluripotency and self-renewal (Warren
et al, 2007). Interestingly, overexpression of SALL4 has been
shown to cause aberrant activation of the WNT pathway in
myelodysplastic syndromes (Shuai et al, 2009), and SALL4
expression has recently been linked to gastric cancers
(Ushiku et al, 2010). Furthermore, sem-4, the C. elegans
orthologue of SALL4, promotes vulval cell fate
determination. TSC22d2 is a member of the TSC22 (TGFb-
stimulated clone 22) family of putative transcription factors
that is activated by TGFb1 receptor signalling (Jay et al,
1996). Tsc22 has been shown to be expressed at sites of
epithelial mesenchymal interactions from the early stages of
mouse development (Dohrmann et al, 1999). Indeed when
we performed ISH analysis of intestinal tissue from Nrbp1
cKO mice, Tsc22d1 and Tsc22d4 were both strongly expressed
in the pericryptal fibroblasts while Tsc22d2 was expressed
primarily in the crypt regions (Supplementary Figure 6)
suggesting a possible role in signalling from the intestinal
Figure 6 Associations of altered NRBP1 expression with human cancers. (A) Expression analysis of NRBP1 in human large-cell lung
carcinoma, lung adenocarcinoma, T-cell prolymphocytic leukaemia, colorectal carcinoma, cutaneous follicular lymphoma, marginal zone
B-cell lymphoma and diffuse large B-cell lymphoma compared to relevant normal tissues. *Po0.05, **Po0.01 and ***Po0.001. (B) Survival
analysis of patients with lung adenocarcinoma expressing either high (green) or low (blue) NRBP1 expression levels.
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mesenchyme to cryptal cells. The TSC22 protein family is
conserved between humans and C. elegans, but the function
of these proteins has been difficult to determine due to
differences in isoforms, redundancy, synergistic and/or an-
tagonistic functions (Gluderer et al, 2010). Much of the work
on these proteins has been carried out in Drosophila, and the
data have suggested genetic interactions with the fly
orthologues of BMP, WNT, HH, NOTCH and components of
the EGFR signalling pathway (Treisman et al, 1995; Dobens
et al, 2000; Dobens et al, 2005). Furthermore, in this system
the fly orthologue of NRBP1 (Madm) and the long isoform of
TSC22, Bunched (bunA), have been shown to directly bind,
and loss of either protein leads to similar growth phenotypes.
It is interesting to note that TSC22D1 has been shown to be
highly induced by oncogenic RAS expression and together
with TSC22D4 regulate oncogene-induced senescence
(Homig-Holzel et al, 2011).
In conclusion, using a novel combination of RNAi screens
in worms together with detailed follow-up experiments in
mouse and human cells, we show that NRBP1 is a tumour
suppressor that plays a critical role in intestinal cell homo-
eostasis. Crucially, NRBP1 levels are reduced in a wide variety
of human tumours and, furthermore, reduced NRBP1 levels in
lung cancer correlates with a poor prognosis.
Materials and methods
C. elegans RNAi
Nematode strains used in this work were provided by the
Caenorhabditis Genetics Centre. Screening was performed at 16 1C in
12-well plates using 715 bacterial RNAi clones (Supplementary
Table 3) to target 656 transcripts with kinase or kinase-like motifs
from the Ahringer library (Kamath et al, 2003). Bacterial RNAi feeding
strains were grown overnight in 2TYplus 100mg/ml ampicillin at 37 1C
and spotted onto plates containing LB, 100mg/ml ampicillin and 4 mM
IPTG. Approximately 10 L4 staged worms were dispensed to the first
well of each row and grown for 72 h, after which 1 adult worm was
moved to a separate well and left overnight before removal. Embryos
were left to mature for at least 72 h and scored for Muv in 100–200
animals in triplicate by visual inspection using a dissecting
microscope. Muv was scored in comparison to the phenotype of the
worm strain alone. The top and bottom 2% of genes were retested in
two separate confirmatory rounds of screening. For egl-17Hcfp assays,
L3 animals were mounted and examined for persistent expression of
egl-17Hcfp prior to L4.
Cell culture, transformation assays and luciferase assays
All cell lines (NIH3T3, HEK 293, BJ-ET-st p53kd,p16kd, SW480 and
HCT-116) were cultured in DMEM supplemented with 10% fetal
bovine serum and glutamine/penicillin/streptomycin. For focus
formation assays, NIH3T3 cells were transfected using lipofecta-
mine (Invitrogen) with 200 ng of pBabe-RasV12 plasmid DNA
together with 200 ng of pRS shRNA plasmid DNA designed against
Nrbp1 (the sequence of shRNA hairpins is provided in the
Supplementary methods) or an empty vector control. Cells were
seeded at 1105 per 6-cm plate and fed every 4 days for 2 weeks
and then stained with methylene blue and foci were counted. Each
experiment involved five replicate transfections performed on three
separate occasions. BJ-ET-st p53kd,p16kd soft agar assays were
performed as described previously (Voorhoeve and Agami, 2003)
with human pRS shRNAs (provided in Supplementary methods),
which were modified to introduce a blasticidin resistance cassette
driven by the PGK promoter. Data were statistically analysed using
the Mann–Whitney U-test. Luciferase assays were performed in
24-well plates with 7.5103 HCT-116 or HEK 293 cells. Cells were
cotransfected using lipofectamine with either 200 ng NRBP1 shRNA
vectors or empty vector in combination with either 150 ng M50
Super 8x TOPFlash or M51 Super 8 FOPFlash and 50 ng Renilla
(pRL-SV40) plasmid. At 72 h after transfection, cells were lysed in
100-ml passive lysis buffer, and the dual luciferase assay performed
according to the manufacturers protocol (Promega). The relative
luciferase activity was calculated against Renilla activity. Each
shRNA was assayed in experiments involving six replicates and
these experiments were performed on at least two separate occa-
sions. Data were statistically analysed using ANOVA. CellSensor
assays were performed in 96-well plates with 2.4104 SW480 cells.
Cells were transiently transfected with 20 nm siRNA (Dharmacon)
using Lipofectamine RNAimax (Invitrogen). At 72 h after transfec-
tion FRET read-out was measured using beta-lactamase loading
solution (Invitrogen) by standard procedures. Data were statistically
analysed using ANOVA. Ex vivo crypts were isolated from Nrbp cKO
and control mice small intestine by incubating in 2 mM EDTA in
PBS. Crypt cultures were grown in Matrigel (BD biosciences) and
provided with Advanced DMEM/F23 (Invitrogen) supplemented
with N2 (Invitrogen), B27 (Invitrogen), EGF (Peprotech), NOGGIN
(Peprotech) and mR-Spondin (R&D Systems) (Sato et al, 2009).
Adenoviral infection of crypts was performed by mechanically
separating crypts away from Matrigel and incubating with Adeno-
Cre or Adeno-GFP (as a control) virus at 37 1C for 3–4 h before
re-plating in Matrigel. GFP expression was seen in B80% of cells
the day after infection.
Mice
To generate the Nrbp1 targeting vector, DNA fragments for the
50- and 30-homology arms were amplified from bMQ-76E6 BAC (Adams
et al, 2005) by PCR using the following primers: Capture arms1F—AA
AAAAAAAAGAGCTCCTGGTCCTGTAGTTTTAGATTCCATG, Capture
arms1R—TTT TTTTTTTGAATTCAAAGCGATACCCTGGAAAGTAAA
CT, Capture arms2F—AAAAAAAAAAGAATTCACGGGCACTGGGGA
AGCTGAGTTCTA, Capture arms2R—TTTTTTTTTTGGTACCCATCT
GCAAGGTAGGGGGAGGGGCGG, and cloned into pBS SK(þ ). The
linear gap repair plasmid was transformed into EL350 cells carrying
the bMQ-76E6 BAC (Liu et al, 2003) and gap-repaired plasmids were
selected for ampicillin resistance. A LoxP site was inserted into
intron 4 and a PGK–neomycin selection cassette flanked by Frt sites
and a second LoxP site were introduced into intron 11 of the
captured Nrbp1 DNA fragment. Targeting was performed in E14J
(129P2/Ola) ES cells and germline chimeras were transmitted onto
a C57BL/6J background. Southern blot analysis of BamHI-digested
DNA was performed using 50- and 30-probes using standard proce-
dures (50-ProbeF—GAGGCTTTCTGGGTTTCCTC, 50-ProbeR—CGGG
GCACTTAGAGAAAAGA, 30-ProbeF—GTTCGGGACTACTGGTGAGC
and 30-ProbeR—TGGCAATCAGCAATAAGACG). Mice were geno-
typed by PCR using the primers: A—GAA AAG GTC CGT GCA
GTG TT, B—AGA TGG CAG TGC TGG AGA TT and C—CAA GCG
TTC TTG TTC AGA CG. Male Nrbp1 mice carrying the unmodified
targeted allele of Nrbp1 were crossed with either CMV-Cre (Su et al,
2002) or 129S4/SvJaeSor-Gt(ROSA)26Sortm1(FLP1)Dym/J (FLPeR) mice
(Farley et al, 2000) to produce Nrbp1þ / and Nrbp1flox/þ mice,
respectively. RosaCreERT2/þ mice (Vooijs et al, 2001) were used for
somatic deletion of Nrbp1, and Cre-mediated site-specific
recombination was performed in mice aged 7–8 weeks carrying
the RosaCreERT2/þ allele by intraperitoneal injection with either
100ml of 40 mg/ml tamoxifen base in sunflower oil for three
consecutive days or 100ml of 10 mg/ml tamoxifen base in
sunflower oil for four consecutive days. Mice that became
moribund were euthanized, and tissues collected and fixed in 10%
neutral buffed formalin. H&E staining was performed using standard
procedures. All procedures with animals were carried out in
accordance with Home Office UK guidelines
Immunohistochemistry, ISH and immunoblotting
Immunostaining was performed on 4-mm sections using the DAKO
Autostainer Plus with the rabbit VECTASTAIN ELITE ABC horse-
radish peroxidase kit (Vector Laboratories). For primary antibodies,
see Supplementary methods. In all cases, a total of 30 crypts/villi
were counted from the small intestine of four Nrbp1flox/flox
RosaCreERT2/þ and control mice. Four lengths of intestinal epithe-
lium were photographed and used to estimate crypt numbers of
Nrbp1flox/floxRosaCreERT2/þ , Nrbp1flox/floxRosaCreERT2/þ and Nrbp1flox/þ
RosaCreERT2/þ mice (four of each genotype). All comparisons were
made using the Mann–Whitney U-test. Western blotting was per-
formed using standard methods. For primary antibodies see
Supplementary methods. Activation of Ras was analysed using
Active Ras Pull-Down Detection Kit, which contains GST–Raf1–
RBD fusion protein (Thermo scientific) in accordance with the
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manufacturer’s instructions. ISH was performed with 6-mm sections
on the automated Ventana Discovery platform with RiboMap and
BlueMap Kits (Ventana) and DIG-labelled riboprobes (primers for
generating probes are available in the Supplementary methods).
Immunopreciptiations were performed with either HEK293 cells or
mouse embryonic stem cells using a FLAG Immunoprecipitation Kit
(Sigma). HEK293 cells were transiently trasfected with the follow-
ing expression plasmids: NRBP1-Flag-MSCV, pcDNA3-myc-CUL5
(Ohta et al, 1999) and c-Myc-Elongin B and HSV-Elongin C
(Brower et al, 1999). Elongin B and Elongin C siRNAs pools were
purchased from Thermo scientific. ES cells were stably integrated
with NRBP1-Flag-MSCV after selection with neomycin.
qRT–PCR and microarray analysis
Total RNA was isolated from snap-frozen small intestine using
TRIzol (Invitrogen), DNase treated using Turbo DNase (Ambion)
and 2 mg total RNA reverse transcribed using the BD Sprint kit with
random hexamers (ABI) according to the manufacturer’s protocols.
qRT–PCRs were performed with SYBR Green (ABI) on the ABI
StepOnePlus Real-Time PCR Systems in accordance with the man-
ufacturer’s instructions (see Supplementary methods for primer
sequences). The final quantitation was determined using the stan-
dard curve method relative to the house-keeping genes Gapdh or
Actb. Data were statistically analysed using ANOVA. Microarray
analysis was performed on total RNA using the Illumina mouse-6
expression beadchip version 2 platform (Illumina) by standard
procedures. Probe summaries were calculated in BeadStudio and
quantile normalised. A linear model fit was applied and the top
differentially expressed genes were tabulated for each contrast
using the Benjamini and Hochberg method to correct the P-values.
The Molecular signatures database MSigDB Version 2.5 (http://
www.broadinstitute.org/gsea/msigdb/index.jsp) was used to com-
pute overlaps between the top and bottom 500 most differentially
expressed genes to gene sets in MSigDB (Subramanian et al, 2005).
Tandem affinity purification mass spectrometry analysis
The protocol used for the purification of proteins has been de-
scribed previously (Pardo et al, 2010). Briefly, HEK293 and ES cells
expressing the CBP2TEV3FLAG tag were lysed and incubated with
anti-FLAG M2 Dynal beads (Sigma). TEV eluates from mouse
ES cells were subsequently incubated with calmodulin resin
(Stratagene), from which protein complexes were eluted by Ca
chelation with EGTA. For single affinity purifications from
HEK293 cells, the second purification step was omitted. EGTA and
TEV eluates were separated by one-dimensional SDS
electrophoresis. Gel lanes were excised, digested with trypsin and
peptides extracted with 0.5% formic acid–50% acetonitrile.
Peptides were analysed with on-line nanoLC-MS/MS on a LTQ FT
mass spectrometer (ThermoElectron) coupled with an Ultimate
3000 Nano/Capillary HPLC System (Dionex). The LC used a
PepMap C18 trap (0.3 mm id 5 mm, LC Packings) and a BEH
C18 analytical column (75 mm id 10 cm, Waters) with a 30 min
linear gradient of 4–32% CH3CN/0.1% formic acid. The LTQ FT
was operated in standard data dependent acquisition. The survey
scans (m/z 400–2000) were acquired on the FT-ICR at a resolution
of 100 000 at m/z 400. The top four multiply charged ions were
subject to MS/MS in the linear ion trap at an isolation width of 2 Th.
Dynamic exclusion width was set at ±20 p.p.m. for 45 s. The
automatic gain control target value was regulated at 5E5 for FT
and 1E4 for the ion trap, with maximum injection time at 1000 ms
for FT and 200 ms for ion trap, respectively. The raw files were
processed with BioWorks (Thermo). Database searches were
performed with Mascot v.2.2 (Matrix Science) against the Human
or mouse IPI database (v. December 2008). The search
parameters were: Trypsin/P with two missed cleavages, 10 p.p.m.
mass tolerance for MS, 0.5-Da tolerance for MS/MS, fixed modi-
fication carbamidomethyl (C), and variable modifications of
Acetyl (Protein N-term), Deamidated (NQ), Dioxidation (M),
Formyl (N-term), Gln-4pyro-Glu (N-term Q), Methyl (E) and
Oxidation (M). Decoy database searches were performed at the
same time as the real searches, resulting in false discovery rates
under 5%.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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